| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 03/24/2005 | US20050064023 Lipid linked to a delivery, targeting or stabilising moiety (DTS moiety) via a linker which is stable in biological fluid and which is unstable in defined conditions, forms a complex with a therapeutic agent; for non-viral gene transfer |
| 03/24/2005 | US20050064022 Contains amorphous terazosin; treating benign prostatic hypertrophy; maximizes the dosage interval and minimizes the plasma concentrations and or fluctuations in plasma concentrations |
| 03/24/2005 | US20050064021 Medical dressings |
| 03/24/2005 | US20050064017 feeding dog or cat the pet food including 5-40% by weight protein, 5-45% by weight fat, 0.1 to 12% by weight fiber, 1 to 90% by weight digestible carbohydrate, 0.1-2% by weight functional ingredient to build lean muscle mass |
| 03/24/2005 | US20050064012 instilling a bio-compatible material containing bio-compatible molecules to the cornea of the eye, cornea has a first composite refractive index, such bio-compatible molecules alter first composite refractive index to a second composite refractive index |
| 03/24/2005 | US20050064010 Transscleral delivery |
| 03/24/2005 | US20050064009 Implantable device for treating disease states and methods of using same |
| 03/24/2005 | US20050064008 Solid or semi-solid therapeutic formulations |
| 03/24/2005 | US20050064005 Active agent delivery systems including a miscible polymer blend, medical devices, and methods |
| 03/24/2005 | US20050063998 completely dissolving galantamine or salt , intense sweetener, in a bulk liquid carrier to form a solution, diluting the solution with purified wate; Alzheimer disease and related dementia, mild cognitive impairment (MCI), Lewy body disease (LBD), Parkinson disease, schizophrenia |
| 03/24/2005 | US20050063997 Mixture of macrolactone antibodies and mycophenolic acid ; antiinflammatory agents; antiproliferative agents; topical drug |
| 03/24/2005 | US20050063996 Ocular solutions |
| 03/24/2005 | US20050063980 An alginate, a pectin and an antacid, such as sodium or potassium bicarbonate; gastrointestinal reflux disease |
| 03/24/2005 | US20050063957 Antibacterial therapy with bacteriophage genotypically modified to delay inactivation by the host defense system |
| 03/24/2005 | US20050063949 Method of treating hepatitis virus infection with a multiphasic interferon delivery profile |
| 03/24/2005 | US20050063941 Biodegradable polymeric material for biomedical applications |
| 03/24/2005 | US20050063940 Use of (poly)ethoxylated fatty acid glycerides for enhancing bioadhesion of a liquid pharmaceutical applied to a mucous membrane; use delivering active agents to plants, fish gills |
| 03/24/2005 | US20050063930 Topical formulation of the oil-in-water type, comprising galactolipid material as emulsifier, with a prolonged effect of an incorporated active substance |
| 03/24/2005 | US20050063926 Comprises polyetherurethanes and nitrocellulose dispersed in carrier containing tackifier resin (polyterpene); for barrier teat dips, protecting cows against mastitis, especially during non-lactating periods |
| 03/24/2005 | US20050063921 Oral composition |
| 03/24/2005 | US20050063920 Oral composition |
| 03/24/2005 | US20050063916 Aerosol cosmetic composition |
| 03/24/2005 | US20050063913 Novel metaxalone compositions |
| 03/24/2005 | US20050063912 Process for manufacturing bulk solutions and a lyophilized pure alpha-aztreonam lysinate |
| 03/24/2005 | US20050063911 Accurate metered single inhalation administration |
| 03/24/2005 | US20050063909 Drug and adverse-effect agent coated with inner acid-soluble layer and outer base-soluble layer; sustained release; multilayer tablets; for treatment of pain with opiod analgesics |
| 03/24/2005 | US20050063907 Radioopaque sustained release pharmaceutical system |
| 03/24/2005 | US20050063906 Device and method for examining a body lumen |
| 03/24/2005 | US20050063686 Device, method and resistive element for vaporising a medicament |
| 03/24/2005 | US20050061678 Treatment of humans with colloidal silver composition |
| 03/24/2005 | US20050061314 Metered dose inhaler |
| 03/24/2005 | DE10357640A1 Cosmetic or dermatological composition based on water-in-oil emulsion is in the form of solid, semisolid or dimensionally stable spheres, spheroids or other shaped bodies |
| 03/24/2005 | DE10357639A1 Kosmetische und/oder dermatologische Kapsel Cosmetic and / or dermatological capsule |
| 03/24/2005 | DE10340428A1 Opioides Analgetikum enthaltende transdermale Formulierung Opioid analgesic containing transdermal formulation |
| 03/24/2005 | DE10339863A1 Quellsubstratpellets als orale Darreichungsform für Ballaststoffe Source substrate pellets as an oral dosage form of fiber |
| 03/24/2005 | DE10339197A1 Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität Spray-dried amorphous powder having a low residual moisture content and good storage stability |
| 03/24/2005 | DE10338544A1 Film for buccal administration comprises galanthamine and polymer layer, useful for treating diseases associated with defective acetylcholine-mediated signal transduction and/or dysregulation of neuronal nicotinic receptors |
| 03/24/2005 | DE10338391A1 Carrier for administration of tablets or capsules to cats or other animals comprises a shapeable 'gum-like' or shape-retaining 'rubber bar' product |
| 03/24/2005 | DE10338174A1 Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit Transdermal drug formulations with drug combinations for the treatment of Parkinson's disease |
| 03/24/2005 | DE10337697A1 Tablette enthaltend Tablet containing 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze or salts thereof |
| 03/24/2005 | DE10336400A1 Gegen Missbrauch gesicherte Darreichungsform Abuse-proofed dosage form |
| 03/24/2005 | DE10111767B4 Verfahren zur Herstellung von Polyestern aus Hydroxycarbonsäuren und Polyolen durch Polykondensation A process for the preparation of polyesters of hydroxycarboxylic acids and polyols by polycondensation |
| 03/24/2005 | CA2810312A1 Novel crystalline polymorphs of clopidogrel |
| 03/24/2005 | CA2809750A1 Novel crystalline polymorphs of clopidogrel |
| 03/24/2005 | CA2551022A1 Polyethyleneglycol-modified lipid compounds and uses thereof |
| 03/24/2005 | CA2542303A1 A composition and method of treatment for urogenital conditions |
| 03/24/2005 | CA2539041A1 Dry powder composition comprising a benzodiazepine for pulmonary inhalation |
| 03/24/2005 | CA2539033A1 Treatment of disease or injury of the nervous system with fty720 |
| 03/24/2005 | CA2538997A1 Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation |
| 03/24/2005 | CA2538929A1 Enteric delivery of (-)-hydroxycitric acid |
| 03/24/2005 | CA2538755A1 Granular jelly drink capable of masking bitterness |
| 03/24/2005 | CA2538399A1 Pharmaceutical compostions |
| 03/24/2005 | CA2538333A1 Multi-system therapy for diabetes, the metabolic syndrome and obesity comprising a hypoglycemic agent |
| 03/24/2005 | CA2538237A1 Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation |
| 03/24/2005 | CA2537820A1 Process for preparing water-soluble medicaments comprising complexation of forskolin in cyclodextrins |
| 03/24/2005 | CA2537343A1 Treatment of gastroparesis and nonulcer dyspepsia with gabab agonists |
| 03/24/2005 | CA2537250A1 Topical preparations comprising a hydrophilic carrier and a silicone matrix |
| 03/24/2005 | CA2535373A1 Methods for the controlled delivery of pharmacologically active compounds |
| 03/24/2005 | CA2530510A1 Improved delivery by labile hydrophobic modification of drugs |
| 03/24/2005 | CA2504885A1 Agent containing ergolin for transdermal application |
| 03/23/2005 | WO2005030935A2 Adjuvant activities of mutants of lt-iia and lt-iib enterotoxin lacking binding to ganglioside |
| 03/23/2005 | EP1516866A1 Natural compounds and derivatives thereof for the prevention and treatment of cardiovascular, hepatic and renal diseases and for cosmetic applications |
| 03/23/2005 | EP1516662A1 Preparation comprising at least two nanoemulsions |
| 03/23/2005 | EP1516639A1 Device in the treatment of pulmonary vasoconstriction and asthma |
| 03/23/2005 | EP1516636A2 Use of a curable elastomer-precursor for a medical treatment |
| 03/23/2005 | EP1516631A1 Body ointment having decongestant effect and for the progressive relief of muscular pain, sprains, wrenchs, dislocations, aches and for relief of articular and rheumatic pain |
| 03/23/2005 | EP1516624A1 Method of producing calcium gluconolactate, compositions, processes and uses of same |
| 03/23/2005 | EP1516622A1 Stable diltiazem hydrochloride pharmaceutical composition for cutaneous application and process for the preparation thereof |
| 03/23/2005 | EP1516616A1 A controlled-release preparation having specific pore forming agents in the coating |
| 03/23/2005 | EP1516615A2 Solid delivery systems for controlled release of molecules incorporated therein and methods of making same |
| 03/23/2005 | EP1516614A1 Method of preparing particles for agglomeration |
| 03/23/2005 | EP1516597A1 Drug eluting stent |
| 03/23/2005 | EP1516542A1 Nutritional supplement to treat macular degeneration |
| 03/23/2005 | EP1516283A1 Actuation indicator for a dispensing device |
| 03/23/2005 | EP1516185A2 Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor |
| 03/23/2005 | EP1515978A1 Sulfur-containing phospholipid derivatives |
| 03/23/2005 | EP1515974A2 Novel maxi-k channel blockers, methods of use and process for making the same |
| 03/23/2005 | EP1515766A1 Method and packaging for pressurized containers |
| 03/23/2005 | EP1515751A1 Stabilised pharmaceutical compositions on the basis of polyoxyethylated castor oil and method for manufacturing the same |
| 03/23/2005 | EP1515744A2 Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b |
| 03/23/2005 | EP1515741A1 Composition comprising viscous fibers and viscosity-lowering proteins |
| 03/23/2005 | EP1515740A1 Aqueous preparation containing oligopeptides and etherified cyclodextrin |
| 03/23/2005 | EP1515734A1 Honey-based skin care preparation |
| 03/23/2005 | EP1515722A2 Ophthalmic compositions for treating ocular hypertension |
| 03/23/2005 | EP1515721A1 Ophthalmic compositions for treating ocular hypertension |
| 03/23/2005 | EP1515712A2 Use of taurine for the treatment of alopecia |
| 03/23/2005 | EP1515706A2 A platform for transdermal formulations (ptf) |
| 03/23/2005 | EP1515705A1 Fluorosiloxane matrix controlled diffusion drug delivery system |
| 03/23/2005 | EP1515704A1 Microcapsules for the delayed, controlled release of perindopril |
| 03/23/2005 | EP1515703A1 Pharmaceutical compositions with improved dissolution |
| 03/23/2005 | EP1515702A1 Abuse-protected administration form |
| 03/23/2005 | EP1515701A1 Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them |
| 03/23/2005 | EP1515700A2 Controlled alignment of catalytically grown nanostructures in a large-scale synthesis process |
| 03/23/2005 | EP1515699A1 Process for loading and thermodynamically activating drugs on polymers by means of supercritical fluids |
| 03/23/2005 | EP1515698A2 Liposomes containing biologically active compounds |
| 03/23/2005 | EP1515697A1 Short duration depot formulations |
| 03/23/2005 | EP1515690A2 Breath freshening and oral cleansing product with magnolia bark extract |
| 03/23/2005 | EP1515682A1 Biliquid foam entrapment |
| 03/23/2005 | EP1515674A1 Abuse-resistant opioid solid dosage form |
| 03/23/2005 | EP1515618A1 Nano-sized self-assembled structured liquids |